+ Watch ALIM
on My Watchlist
Short. Biopharma. $0 Revenues. Consistent share dilution.
This stock has been growing over the past few weeks. It seems that the growth is constant and should continue to grow over the next few weeks.
went up 244% for portefeille.
This is a huge need in Ophthalmology patient care. Patients are enduring numerous injections into the eye to decrease edema and the progressive damage it can create. This time-released med will last a long time while decreasing risk and cost to the patient.
There are currently 2200 ALIM shares in my "fund" with break-even of around 5.81 USD.http://caps.fool.com/Blogs/fund-trades/678775.
European approval will help lift it from the basement of FDA rejection!
Diabetes Diabetes Diabetes. americans are unhealthy
First FDA rejection was fairly benign. Investors will come back as second decision approaches.
oversold on FDA news
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions